ECSP003851A - Composicon de liberacion doble de un inhibidor ciclooxigenasa-2 - Google Patents

Composicon de liberacion doble de un inhibidor ciclooxigenasa-2

Info

Publication number
ECSP003851A
ECSP003851A EC2000003851A ECSP003851A ECSP003851A EC SP003851 A ECSP003851 A EC SP003851A EC 2000003851 A EC2000003851 A EC 2000003851A EC SP003851 A ECSP003851 A EC SP003851A EC SP003851 A ECSP003851 A EC SP003851A
Authority
EC
Ecuador
Prior art keywords
release
cyclloxygenasa
inhibitor
release composition
double release
Prior art date
Application number
EC2000003851A
Other languages
English (en)
Inventor
Sreekant Nadkarni
Subhash Desai
Randy J Wald
Gary A Debrincat
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of ECSP003851A publication Critical patent/ECSP003851A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composciones farmacéuticas son proveídas comprendiendo una o mas unidades de dosis oralmente liberables, cada uno comprende una droga inhibidora selectiva de ciclooxigenasa-2 de baja solubilidad en agua en un fragmento de liberación inmediata y uno de liberación controlada, liberación lenta, liberación cronometrada, liberación a pulso, liberación sostenida o fragmento de liberación extendida. Las composiciones son útiles en el tratamiento o profilaxis de condiciones y enfermedades causadas por ciclooxigenasa-2.
EC2000003851A 1999-12-22 2000-12-22 Composicon de liberacion doble de un inhibidor ciclooxigenasa-2 ECSP003851A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17173899P 1999-12-22 1999-12-22

Publications (1)

Publication Number Publication Date
ECSP003851A true ECSP003851A (es) 2002-05-23

Family

ID=30442469

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2000003851A ECSP003851A (es) 1999-12-22 2000-12-22 Composicon de liberacion doble de un inhibidor ciclooxigenasa-2

Country Status (3)

Country Link
US (1) US20070202170A1 (es)
EC (1) ECSP003851A (es)
ZA (2) ZA200204592B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9452107B2 (en) * 2012-04-16 2016-09-27 New Jersey Institute Of Technology Systems and methods for superdisintegrant-based composite particles for dispersion and dissolution of agents
KR20160098029A (ko) * 2015-01-13 2016-08-18 오토텔릭 엘엘씨 개별화된 약물 치료요법을 위한 방법
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6103262A (en) * 1994-01-27 2000-08-15 G. D. Searle & Company Modified-release metronidazole compositions and methods for making and using same
RS49982B (sr) * 1997-09-17 2008-09-29 Euro-Celtique S.A., Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2

Also Published As

Publication number Publication date
US20070202170A1 (en) 2007-08-30
ZA200204593B (en) 2003-08-27
ZA200204592B (en) 2003-12-08

Similar Documents

Publication Publication Date Title
ECSP066313A (es) Derivados de la piridazina y su uso como agentes terapéuticos
NO20013859D0 (no) Cyklooksygenase-2 inhibitorpreparater som raskt gir terapeutisk effekt
UY27939A1 (es) Compuestos
DOP2009000155A (es) Derivados de hetero-pentaciclo-fenilo fusionados, composicion farmaceutica que los comprende y usos para preparar un medicamento util para el tratamiento de una condicion mediada por p38
CR9842A (es) Composiciones de celecoxib
NI200300042A (es) Compuestos que modulan la actividad de ppar y metodos para su preparacion.
PA8547701A1 (es) Nucleosidos 4 substituidos.
ES2376043T3 (es) Derivados de indazol para el tratamiento de enfermedades inducidas por hsp90.
MX2020008616A (es) Rocio de fentanilo sublingual.
PA8577101A1 (es) Nuevos derivados de glicosido de tiofeno, procedimientos para la preparacion de los mismos, medicamentos que contienen estos compuestos, y el uso de los mismos
CR8487A (es) Derivados de indazole como inhibidores de una hormona sensitiva a la lipasa
BR0016705A (pt) Composições de liberação dupla de um inibidor de ciclooxigenase-2
ES2146300T3 (es) Utilizacion de composiciones antihelminticas para el tratamiento de infecciones causadas por anoplocephala perfoliata en equidos.
UY26782A1 (es) Derivados del benzotiazol
ES2174073T3 (es) Forma farmaceutica solida para uso oral.
AR013001A1 (es) Derivados de la piperazina, procedimientos para prepararlos, las composiciones farmaceuticas que los contienen, su utilizacion como medicamentoy el metodo para tratar enfermedades mediadas por la taquinina.
GT200600260A (es) Derivados de benzamida y usos relacionados con los mismos
NO20035438L (no) Farmasoytisk formulering for effektiv administrering av apomorfin, 6aR-(-)-N-propyl-norapomorfin og deres derivater og prodrugs derav
NO20025358D0 (no) Ortosubstituerte antranilsyreamider og deres anvendelse som legemidler
NO20062923L (no) Nye benzofuranderivater som kan anvendes i forebygging eller behandling av 5-HT6 reseptorrelatert forstyrrelse
NO20062703L (no) Maleatsalter av et kinazolinederivater anvenbare som antiangiogenisk middel
ECSP003807A (es) Composiciones valdecoxib
AR012504A1 (es) Utilizacion de derivados de tetrahidropiridina, para la preparacion de medicamentos para el tratamiento de las enfermedades que provocan unadesmielinizacion.
AR049876A1 (es) Composiciones farmaceuticas para tratar enfermedades de la piel que comprenden una combinacion de epinastina y uno o mas minerales adicionales o uno o mas farmacos brutos
UY26895A1 (es) Compuestos de pirazol, composiciones farmacéuticas, y métodos para modular y/o inhibir la actividad de erab/hadh2